Trading Systems Reacting to (BMRN) Volatility
This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN), identifying a neutral near-term outlook despite strong mid-term sentiment potentially stalling. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, showing support and resistance levels. The report highlights an exceptional 27.1:1 risk-reward short setup targeting a 7.6% downside.
BMRN - Biomarin Pharmaceutical Inc Options
This article provides comprehensive financial data for BioMarin Pharmaceutical Inc. (BMRN), including its last close price, market capitalization, income, sales, and various financial ratios. It also details insider ownership, institutional ownership, profitability margins, and stock performance metrics over different periods.
BMRN - Biomarin Pharmaceutical Inc Volatility & Greeks
This article provides a detailed financial overview of BioMarin Pharmaceutical Inc. (BMRN), including its stock performance, key financial metrics, insider and institutional ownership, and various ratios. It covers aspects from market capitalization and earnings per share to volatility, analyst recommendations, and target prices for the company.
BioMarin Pharmaceutical (BMRN) Highlights ENDO 2026 Progress, Is The Stock Undervalued?
BioMarin Pharmaceutical (BMRN) is under analysis after presenting new VOXZOGO and BMN 333 data at ENDO 2026 and releasing mixed quarterly results with updated guidance. The stock shows short-term momentum but is still down over a three-year period. Despite trading at a discount to analyst price targets and intrinsic value, there's a debate on whether this undervaluation reflects future growth or market overestimation.
Enterprise value to revenue forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN
This article focuses on the enterprise value to revenue forward metric for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). It appears to be a stub or a section of a larger financial analysis provided by TradingView, indicating a specific financial valuation ratio for the company.
Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
This page provides an overview of Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (BMFBOVESPA:B1MR34) on TradingView. It offers access to actuals and estimates for financial data, including income statements, balance sheets, cash flow, and valuation metrics, allowing users to compare reported results with analyst estimates. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
BioMarin Pharmaceutical Inc. Actuals & Estimates (NASDAQ:BMRN)
This article provides an overview of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates for revenue, earnings per share, net income, and EBITDA, and states the company's next earnings report is due on August 4, 2026. The article also covers market capitalization, employee count, and stock volatility, advising comprehensive research before investing.
Price to sales forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN
This article displays the forward price-to-sales ratio for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). It presents a specific financial metric for the company as listed on the Nasdaq Stock Market. The content is sparse, mainly serving as a data point within a larger financial information platform.
How Biomarin Pharmaceutical Inc. (BMRN) Affects Rotational Strategy Timing
This article analyzes Biomarin Pharmaceutical Inc. (BMRN) through the lens of rotational strategy timing, highlighting a strong near-term sentiment but a neutral mid and long-term outlook. Predictive AI models have generated three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones for different risk profiles. The analysis also provides multi-timeframe signal analysis, showing varying support and resistance levels.
How Biomarin Pharmaceutical Inc. (BMRN) Affects Rotational Strategy Timing
Quantitative analysis suggests that Biomarin Pharmaceutical Inc. (BMRN) is exhibiting a mid-channel oscillation pattern, with strong near-term sentiment but a neutral mid and long-term outlook. The report identifies an exceptional 28.2:1 risk-reward setup targeting an 8.1% gain versus a 0.3% risk. It provides institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for support and resistance levels.
BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment
BioMarin (BMRN) presented positive Phase 2 extension study data for VOXZOGO (vosoritide) in children with hypochondroplasia, showing sustained improvements in growth parameters over three years. The company plans to submit a supplemental NDA to the FDA in Q3 2026. Additionally, BioMarin shared promising Phase 1 data for BMN 333, an investigational treatment for achondroplasia, suggesting a potential weekly dosing schedule and significant increase in free CNP exposure.
BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment
BioMarin Pharmaceutical Inc. (BMRN) presented positive Phase 2 data for VOXZOGO (vosoritide) in treating hypochondroplasia, showing sustained growth improvements. The company plans to submit a supplemental NDA to the FDA in Q3 2026 based on these results. Additionally, BioMarin shared promising Phase 1 data for BMN 333, an investigational treatment for achondroplasia, suggesting potential for a weekly dosing schedule and significant C-type natriuretic peptide exposure.
10 Most Promising Stocks with Highest Upside Potential
This article highlights BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as one of the most promising stocks with high upside potential, noting its average upside potential of 55.42%. The company recently presented positive clinical data for its treatments for skeletal dysplasias, including sustained improvements from VOXZOGO and promising Phase 1 data for BMN 333, a potential new standard of care for achondroplasia. BioMarin is advancing these therapies to address rare and life-threatening medical conditions with unmet needs.
BioMarin stock maintained at Neutral by H.C. Wainwright on trial data
H.C. Wainwright reiterated a Neutral rating and kept its $50.00 price target on BioMarin Pharmaceutical Inc. following new clinical trial data for VOXZOGO in children with hypochondroplasia. While the Phase 2 extension study showed sustained improvements in growth velocity and height, a previous trial miss in the Phase 3 ENERGY 3 study for ENPP1 deficiency led to an adjustment from an earlier $55 price target. Analysts predict BioMarin will remain profitable this year.
10 Most Promising Stocks with Highest Upside Potential
This article identifies BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) as one of the most promising stocks with high upside potential, highlighting its advancements in treating skeletal dysplasias. BioMarin recently presented positive clinical data for VOXZOGO and BMN 333, indicating sustained improvements and potential new standards of care for rare growth-related conditions. The company plans to submit a supplemental NDA for VOXZOGO in Q3 2026 and is enrolling for a Phase 2/3 study for BMN 333.
Stifel reiterates Hold on BioMarin stock, keeps $68 price target
Stifel maintained its Hold rating and $68 price target for BioMarin Pharmaceutical Inc. after a meeting with company executives. The stock is currently trading below the target, and InvestingPro analysis suggests it is undervalued with "GREAT" financial health. BioMarin plans to update revenue targets for Galafold and PomOp, drive product penetration in global markets, and invest cash flows into R&D.
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk
This article examines three major US pharmaceutical stocks—Insmed (INSM), Viatris (VTRS), and BioMarin Pharmaceutical (BMRN)—that are significantly impacted by the US Section 301 trade investigation into Germany’s pharmaceutical pricing. It analyzes how pricing politics, global operations, and financial structures could affect their future cash flows and investment appeal. The piece highlights the unique risks and opportunities for each company in the changing global pharmaceutical landscape.
BioMarin Pharmaceutical Inc (BMRN) Institutional Confidence
BioMarin Pharmaceutical Inc (BMRN) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 99.80%, indicating strong confidence despite an 8.29% quarter-over-quarter decrease. Andreas Halvorsen is the largest institutional shareholder, holding 7.62 million shares.
BioMarin Pharmaceutical Inc (BMRN) Valuation: PE, PB & Fair Value Analysis
BioMarin Pharmaceutical Inc (BMRN) has a current valuation score of 8.01, placing it 110 out of 157 in the Pharmaceuticals industry. The company's P/E ratio is 39.20, which is significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
BioMarin Pharmaceutical (BMRN) Stock Could Be 36.7% Undervalued After ENDO 2026 Data
BioMarin Pharmaceutical (BMRN) stock is considered 36.7% undervalued, with a fair value of $87.85 against a current price of $55.65, according to a Simply Wall St analysis. This valuation is based on strong revenue growth from therapies like VOXZOGO and BMN 333, despite its current P/E ratio of 40x being higher than the industry average. While the company's rare disease portfolio shows potential, increased competition and R&D costs could impact future earnings, urging investors to conduct further due diligence.
BioMarin Pharmaceutical Inc. Presents New Three-Year VOXZOGO Data in Hypochondroplasia and BMN 333 Early Results At ENDO 2026
BioMarin Pharmaceutical Inc. presented new three-year data for VOXZOGO in hypochondroplasia and early results for investigational BMN 333 in achondroplasia at ENDO 2026. The VOXZOGO data showed sustained improvements in annualized growth velocity and height in children with hypochondroplasia, while BMN 333 demonstrated prolonged systemic exposure and was well tolerated, supporting a weekly dosing schedule for achondroplasia, with a Phase 2/3 study underway.
Vosoritide data support planned FDA submission for hypochondroplasia
BioMarin has reported encouraging 3-year extension data for vosoritide (Voxzogo) in children with hypochondroplasia, showing sustained growth improvements and a favorable safety profile. These findings, alongside early data for BMN 333 in achondroplasia, were presented at ENDO 2026 and will support a planned supplemental New Drug Application submission to the FDA for vosoritide as a potential new indication for hypochondroplasia in Q3 2026. Vosoritide is currently FDA-approved for achondroplasia, and its efficacy in hypochondroplasia aims to address the unmet medical need for this rare skeletal dysplasia.
BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments
BioMarin Pharmaceutical has released positive 3-year data for Voxzogo and early results for BMN 333, both treatments for growth disorders. The announcement highlights the company's ongoing efforts in developing therapies for genetic conditions. Specific details regarding the data and results for BMN 333 were not provided beyond the headline.
BioMarin presents three-year VOXZOGO data for hypochondroplasia
BioMarin Pharmaceutical Inc. presented positive three-year data for VOXZOGO in children with hypochondroplasia, showing improved height standard deviation scores and growth velocity. The company plans to submit a supplemental New Drug Application to the FDA in Q3 2026. Additionally, BioMarin shared promising Phase 1 data for BMN 333 in achondroplasia and is enrolling patients in a Phase 2/3 study for this investigational medicine.
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
BioMarin Pharmaceutical Inc. announced new three-year data from an investigator-led study showing sustained improvements in growth for children with hypochondroplasia treated with VOXZOGO. Additionally, early Phase 1 results for their investigational medicine BMN 333 in achondroplasia support a weekly dosing schedule and its potential as a new standard of care. These findings were presented at ENDO 2026, the Endocrine Society Annual Meeting.
BMRN: Voxzogo Hypochondroplasia Data Will Recast Earnings Power Despite Franchise Uncertainty
BioMarin Pharmaceutical's stock saw its analyst price target decrease slightly due to mixed sentiment regarding its pipeline. Strong Phase 3 data for Voxzogo in hypochondroplasia is seen as a major growth driver, leading some analysts to believe the stock is undervalued. However, cautious views on BMN401's mixed ENPP1 deficiency results have led other analysts to reduce its probability of success and trim overall expectations.
BioMarin shares drop 4% as Voxzogo trials are discontinued
BioMarin Pharmaceutical Inc. saw its shares drop by 4% after the company announced the discontinuation of two clinical trials for its drug Voxzogo. The decision followed an interim analysis which determined the trials were unlikely to meet their primary endpoints. This news impacts the company's stock performance.
BMRN Technical Analysis & Stock Price Forecast
BioMarin Pharmaceutical Inc. (BMRN) shows a "Strong Buy" technical consensus according to Intellectia.AI, with 12 buy signals and 4 sell signals from 16 technical indicators, as of June 9, 2026. Key indicators like MACD and several moving averages suggest a buy, though the RSI is neutral and some oscillators flash sell signals. The stock is trading near its resistance level with important support levels identified.
10 Most Undervalued Stocks to Buy and Hold for 2 Years
This article identifies BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) as one of the most undervalued stocks to buy and hold for two years, highlighting its strong Q1 2026 financial results, increased revenue guidance due to recent acquisitions, and advancements in its clinical pipeline. The company reported $766 million in Q1 revenue and projects full-year 2026 revenue of $3.825 to $3.925 billion, representing 20% year-over-year growth. BioMarin's focus on scaling its commercial portfolio and innovation pipeline aims to drive long-term value for patients and shareholders, despite the article suggesting higher potential returns from AI stocks.
10 Most Undervalued Stocks to Buy and Hold for 2 Years
This article identifies BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as one of the most undervalued stocks to buy and hold for two years, citing its strong Q1 2026 revenues of $766 million and an increased full-year revenue guidance of $3.825 to $3.925 billion. The company's growth is attributed to the acquisition of Amicus Therapeutics and progress in its clinical pipeline, including FDA approvals and positive clinical data. BioMarin maintains a solid financial position with approximately $2 billion in cash reserves, despite securing $3.7 billion in debt for the acquisition.
BioMarin (BMRN) director gets 7,490 RSUs, holds 21,045 shares
BioMarin Pharmaceutical Inc. director Barbara W. Bodem was granted 7,490 restricted stock units (RSUs) on June 2, 2026, as compensation. This transaction, reported on a Form 4 filing, involved no purchase price for the units. Following this grant, Bodem directly holds a total of 21,045 shares of BioMarin common stock.
BioMarin (BMRN) director receives 7,490 RSUs in stock grant
BioMarin Pharmaceutical director Elizabeth M. Anderson was granted 7,490 restricted stock units (RSUs) on June 2, 2026, as part of her compensation. This transaction, revealed in a Form 4 filing, involved no cash cost and increased her direct holdings to 41,940 shares of BioMarin Common Stock. The grant is a routine compensation-related award rather than a discretionary trading decision.
BioMarin (NASDAQ: BMRN) director receives 7,490-share RSU grant
BioMarin Pharmaceutical director Timothy P. Walbert was granted 7,490 shares of common stock as restricted stock units on June 2, 2026. This equity grant, valued at $0.00 per share, increases his direct holdings to 17,270 shares, with an additional 416 shares held indirectly through Prairie Capital Ventures LLC. The filing indicates stock-based compensation rather than a market transaction and reflects his updated ownership stake in the company.
Director at BioMarin (NASDAQ: BMRN) awarded 7,490 RSUs
BioMarin (NASDAQ: BMRN) director Robert J. Hombach was granted 7,490 restricted stock units (RSUs) on June 2, 2026, as a compensation award. This transaction, which had a price per share of $0.00, increased his direct holdings to 49,360 shares of BioMarin common stock. RSUs are a form of equity compensation that vest over time and encourage long-term employee commitment.
BioMarin (BMRN) director Willard H. Dere receives 7,490-share RSU grant
BioMarin Pharmaceutical Inc. director Willard H. Dere was granted 7,490 restricted stock units (RSUs) on June 2, 2026. This compensation award, with a reported price of $0.00 per share, increases his direct holdings of BioMarin common stock to 46,440 shares. The transaction was disclosed via a Form 4 SEC filing, indicating it was an acquisition-type entry.
BioMarin (BMRN) director Ian T. Clark awarded 7,490 restricted stock units
BioMarin Pharmaceutical Inc. director Ian T. Clark was awarded 7,490 restricted stock units (RSUs) on June 2, 2026, as an equity grant with no cash price per unit, increasing his direct holdings to 14,490 common shares and units. This transaction was reported in a Form 4 filing and represents a compensation-based equity acquisition rather than a market purchase. The RSUs are a type of company reward where full ownership is contingent upon meeting specific conditions, often used to motivate employees.
Shareholders of BioMarin (NASDAQ: BMRN) back equity plan and board slate
BioMarin Pharmaceutical Inc. shareholders approved an amendment to the company's 2017 Equity Incentive Plan, increasing shares reserved for issuance by 7,650,000. All ten director nominees were elected, and KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2026. Additionally, shareholders gave advisory approval to the compensation of the company’s named executive officers.
BioMarin gains on Voxzogo phase 3 results
The article states that BioMarin Pharmaceutical Inc. (BMRN) stock experienced gains following positive interim results from its global Phase 3 clinical study of Voxzogo (vosoritide). The study evaluated older children and adolescents with achondroplasia.
BioMarin Pharmaceutical Hits Day High with 8.63% Surge in Stock Price
BioMarin Pharmaceutical's stock saw an 8.63% surge, reaching an intraday high of USD 57.51, contrasting with the S&P 500's modest gain. While the company has shown positive weekly performance, its longer-term outlook includes year-to-date and three-year declines, as well as reduced pre-tax and net profits. These movements highlight the dynamic nature of the pharmaceuticals and biotechnology sector.
Responsive Playbooks and the BMRN Inflection
The article discusses Biomarin Pharmaceutical Inc. (BMRN), highlighting a strong near-term sentiment but a neutral mid- and long-term outlook. It details an exceptional 29.2:1 risk-reward setup, targeting an 8.5% gain versus 0.3% risk. The analysis includes various AI-generated trading strategies and multi-timeframe signal analysis for BMRN.
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development
BioMarin Pharmaceutical Inc. (BMRN) is highlighted as a stock with potential for significant growth by 2030, driven by its pipeline development. The company recently announced positive Phase 3 study results for VOXZOGO in children with hypochondroplasia, exceeding expectations and leading to planned supplemental New Drug Application submissions. Despite a neutral rating from H.C. Wainwright, the article suggests BioMarin's innovative therapies for rare genetic diseases could lead to substantial returns.
5 Stocks That Could 10X by 2030
This article lists five stocks with the potential to increase tenfold by 2030, with BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) being the first discussed. BioMarin recently reported positive Phase 3 study results for its drug VOXZOGO, prompting intentions to submit a supplemental New Drug Application to regulatory bodies. The company specializes in therapies for rare genetic diseases, including enzyme replacement and gene therapy.
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, indicating a significant upturn for the sector. The bank believes these companies are reaching a critical inflection point, with successful pipelines translating into profitable and diverse commercial enterprises. Several firms received "Overweight" ratings due to expanding product portfolios, strong clinical pipelines, and potential business development, while Moderna received an "Underweight" rating.
BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead
AnalystConsensusTarget has updated its fair value estimate for BioMarin Pharmaceutical (BMRN) to $89.96, reflecting revised assumptions on various financial metrics and a blend of recent analyst price target adjustments. The company's future is influenced by the planned Amicus acquisition, potential Voxzogo indication expansions, and pipeline developments, all while navigating competitive pressures and recent trial discontinuations. There's a divide among analysts, with some highlighting growth opportunities and others expressing caution regarding Voxzogo's long-term prospects amidst rising competition.
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results
BioMarin Pharmaceutical (BMRN) valuation is in focus following positive Phase 3 trial results for its drug Voxzogo. While the company's shares have seen a short-term rally, longer-term returns remain weak. Analysts currently value BMRN as 41.2% undervalued, indicating potential for growth despite competitive pressure and acquisition costs.
BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia
BioMarin Pharmaceutical Inc.'s drug Voxzogo successfully met its primary endpoint in a late-stage clinical trial for children with hypochondroplasia, a genetic disorder affecting bone growth. The study found that children treated with Voxzogo experienced a significant increase in annualized growth velocity compared to those receiving a placebo. This positive outcome could lead to a new treatment option for this rare condition.
BioMarin: Positive Phase 3 Data for Voxzogo in Hypochondroplasia; Shares Very Undervalued
BioMarin has reported positive Phase 3 data for its drug Voxzogo in treating children with hypochondroplasia, a rare short-stature condition. The study successfully met its primary endpoint, showing that patients treated with Voxzogo grew 2.33 centimeters per year faster than the placebo group and exhibited significant improvements in arm span. Following this announcement, BioMarin's shares increased by nearly 8%.
BioMarin (BMRN) EVP Cristin Hubbard reports 2,318-share tax-withholding disposition
BioMarin Pharmaceutical's EVP, Chief Commercial Officer Cristin Hubbard, reported a tax-related disposition of 2,318 shares of common stock. These shares, valued at $50.20 each, were withheld to cover tax obligations. Following this non-market transaction, Hubbard retains direct ownership of 42,472 shares in the company.
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
BioMarin Pharmaceutical Inc. announced positive Phase 3 results for VOXZOGO® (vosoritide) in children with hypochondroplasia, meeting its primary endpoint with a statistically significant increase in annualized growth velocity. The study also showed improvements in standing height, height Z-score, and arm span, with a safety profile consistent with previous findings. BioMarin plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026.
BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint
BioMarin Pharmaceutical Inc. (BMRN) announced that its Phase 3 ENERGY 3 trial for BMN 401 in children with ENPP1 deficiency met only one of its two co-primary endpoints. While treatment significantly increased plasma inorganic pyrophosphate concentration, it failed to improve critical measures of rickets severity or other secondary endpoints. The company is evaluating the data to determine next steps, expressing disappointment that increased PPi levels did not translate into clinical benefits.
